Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Over the past several years, there has been a surge in blood biomarker studies examining
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …

Mild cognitive impairment (MCI) is characterized by memory loss in the absence of dementia
and is considered the translational stage between normal aging and early Alzheimer's …

Background and Purpose: Neurofilament light chain (NfL) is a promising predictive
biomarker of active axonal injury and neuronal degeneration diseases. We aimed to …

Abstract Background Plasma neurofilament light (NfL) is an indicator of neurodegeneration
and/or neuroaxonal injury in persons with Alzheimer's disease (AD) and a wide range of …

One of the most pressing challenges in the clinical research of neurodegenerative diseases
(NDDs) is the validation and standardization of pathophysiological biomarkers for different …

Objective To investigate serum neurofilament light (sNfL) levels in acute ischemic stroke and
to assess whether sNfL are related to the severity of disease and a potential prognostic …

Background: Alzheimer's disease (AD) is the most common neurodegenerative disease
characterized by progressive memory loss and cognitive impairment. In 2011, the National …

The association between functional connectivity (FC) alterations with amyloid-β (Aβ) and τ
protein depositions in Alzheimer dementia is a subject of debate in the current literature …

Neurofilament light chain (NfL) levels have proved to be a good biomarker in cerebrospinal
fluid (CSF) correlating with the degree of neuronal injury and neurodegeneration. However …